Home > others & > Memantine HCl

Memantine HCl

盐酸美金刚片,Namenda,Ebixa,Axura

Memantine hydrochloride 是金刚胺衍生物，对NMDA受体有较弱到适中的亲和力。

目录号
EY1672
EY1672
EY1672
EY1672
纯度
99.53%
99.53%
99.53%
99.53%
规格
100 mg
500 mg
1 g
5 g
原价
230
392
542
970
售价
230
392
542
970
库存
现货
现货
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Memantine HCl is a CYP2B6 and CYP2D6 inhibitor for recombinant CYP2B6 and CYP2D6 with Ki of 0.51 nM and 94.9 μM, respectively.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Chen, H.S., et al. 1998. Neuroscience 86: 1121-1132.
    [2] Parsons, C.G., et al. 1999. Neuropharmacology 38: 735-767.
    [3] Parsons, C.G., et al. 1993. Neuropharmacology. 32: 1337-1350.
    [4] Zajaczkowski, W., et al. 1997. Neuropharmacology. 36: 961-971.

    分子式
    C12H22ClN    		 分子量
    215.76    		 CAS号
    41100-52-1    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    43 mg/mL    		 Water
    30 mg/mL    		 Ethanol
    43 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT01999894 Autism|Pediatric Autism Drug: Memantine HCl Forest Laboratories|Merz Pharmaceuticals GmbH Phase 2 2009-11-01 2014-01-31
    NCT00988663 Major Depressive Disorder Drug: memantine|Drug: Placebo Jerrry L Lewis|University of Iowa 2009-11-01 2017-03-21
    NCT00638833 Multiple Sclerosis Drug: Memantine|Drug: Placebo Clinica Universidad de Navarra, Universidad de Navarra|H. Lundbeck A/S Phase 2 2007-09-01 2012-06-07
    NCT02233556 Schizophrenia Drug: Memantine National Taiwan University Hospital 2014-02-01 2015-12-10
    NCT01844427 ADHD|Executive Function Deficits (EFD's) Drug: Memantine|Drug: Placebo Massachusetts General Hospital 2013-07-01 2013-09-23
    NCT01054599 Epilepsy Drug: Memantine|Other: Sugar Pill|Drug: Memantine American Academy of Neurology|Forest Laboratories 2009-01-01 2017-01-19
    NCT00986115 Epilepsy Drug: Memantine|Drug: Placebo Michael A. Rogawski, MD, PhD|Forest Laboratories|University of California, Davis 2010-07-01 2012-10-17
    NCT02630888 Bipolar Disorder Drug: Memantine|Drug: Placebo University of Sao Paulo Phase 2 2014-08-01 2015-12-10
    NCT00462228 Traumatic Brain Injury Drug: Memantine|Drug: Placebo University of Missouri-Columbia|Forest Laboratories Phase 4 2007-04-01 2016-11-22
    NCT02304302 Down Syndrome|Intellectual Disability Drug: Memantine|Drug: Placebo University Hospitals Cleveland Medical Center|Alana USA Foundation Phase 2 2014-10-01 2016-09-06
    NCT02811627 Autism Spectrum Disorder Drug: Memantine|Device: Magnetic Resonance Imaging University of Missouri-Columbia Early Phase 1 2016-06-01 2016-09-30
    NCT02353130 Autism Spectrum Disorders Drug: Memantine-XR University of North Carolina, Chapel Hill 2015-07-01 2015-10-23
    NCT02240589 Traumatic Brain Injury Drug: Memantine|Drug: Placebo Indiana University 2014-12-01 2016-09-05
    NCT00551161 Alzheimer Disease Drug: memantine Northwell Health|Forest Laboratories Phase 4 2007-08-01 2013-12-20
    NCT01038128 Bulimia Nervosa|Body Dysmorphic Disorder Drug: Memantine Mclean Hospital 2009-12-01 2015-04-13
    NCT00264238 Obsessive-Compulsive Disorder Drug: Memantine Stanford University Phase 1|Phase 2 2006-01-01 2017-01-17
    NCT00956085 Obsessive-Compulsive Disorder Drug: Memantine New York State Psychiatric Institute Phase 2 2009-08-01 2016-04-18
    NCT01592786 Autism Spectrum Disorder (ASD)|Autism|Autistic Disorder|Asperger's Disorder|Asperger's|Pediatric Autism|Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Drug: Memantine Hydrochloride (HCl) Forest Laboratories Phase 2 2012-06-01 2014-07-15
    NCT00134901 Cocaine-Related Disorders Drug: Memantine|Drug: placebo New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA)|Research Foundation for Mental Hygiene, Inc. Phase 2 2003-03-01 2016-04-06
    NCT01333865 Autism Spectrum Disorders Drug: Memantine Massachusetts General Hospital Phase 4 2010-01-01 2016-02-26

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：